Coherus Oncology (CHRS) Profit After Tax (2013 - 2026)

Coherus Oncology has reported Profit After Tax for 14 years, with the latest figure at -$38.3 million in Q1 2026.

• Quarterly Profit After Tax rose 19.14% year-over-year to -$38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $186.3 million (up 150.94% YoY) and the FY2025 annual result came in at $168.0 million, up 178.01% from the prior year.
• Profit After Tax fell to -$38.3 million in Q1 2026 per CHRS's latest filing, from -$37.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $297.8 million in Q2 2025 and troughed at -$294.6 million in Q4 2024.
• A 5-year average of -$35.7 million and a median of -$42.9 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax sank 269.85% in 2024, then jumped 2404.52% in 2025.
• Over 5 years, Profit After Tax stood at -$58.9 million in 2022, then plunged by 35.3% to -$79.7 million in 2023, then tumbled by 269.85% to -$294.6 million in 2024, then jumped by 87.22% to -$37.6 million in 2025, then slipped by 1.82% to -$38.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$38.3 million, -$37.6 million, and -$35.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.